The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Neuropathy, a debilitating condition affecting millions worldwide, can significantly impair daily life and well-being.

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Four in every 10 cancer patients treated with chemotherapy develop severe ...

In an era where health and wellness are prioritized more than ever, the quest for effective natural remedies has led many to ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...